Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Convertible Debt (2016 - 2020)

Zevra Therapeutics (ZVRA) has disclosed Convertible Debt for 5 consecutive years, with $67.7 million as the latest value for Q4 2020.

  • For the quarter ending Q4 2020, Convertible Debt fell 12.52% year-over-year to $67.7 million, compared with a TTM value of $67.7 million through Dec 2020, down 12.52%, and an annual FY2020 reading of $67.7 million, down 12.52% over the prior year.
  • Convertible Debt was $67.7 million for Q4 2020 at Zevra Therapeutics, down from $77.3 million in the prior quarter.
  • Across five years, Convertible Debt topped out at $89.8 million in Q1 2018 and bottomed at $67.7 million in Q4 2020.
  • Average Convertible Debt over 3 years is $78.7 million, with a median of $77.3 million recorded in 2019.
  • Peak annual rise in Convertible Debt hit 0.98% in 2019, while the deepest fall reached 19.06% in 2019.
  • Year by year, Convertible Debt stood at $78.1 million in 2018, then decreased by 0.98% to $77.3 million in 2019, then decreased by 12.52% to $67.7 million in 2020.
  • Business Quant data shows Convertible Debt for ZVRA at $67.7 million in Q4 2020, $77.3 million in Q4 2019, and $70.6 million in Q3 2019.